Lastly, we sought to develop and assess a final five‐mRNA (UBE2L6, PARP14, IFIH1, IRF2, and GBP4) risk‐based model, which we hoped, could effectively predict clinical outcomes for patients as well as depict the tumor immune infiltration landscape of SKCM. The gene discussed is IFIH1; the disease is neoplasm.